25CA1232 Peo in Interest of PG 09-18-2025
COLORADO COURT OF APPEALS
Court of Appeals No. 25CA1232 Pueblo County District Court No. 23MH8 Honorable Amiel Markenson, Judge
The People of the State of Colorado,
Petitioner-Appellee,
In the Interest of P.G.,
Respondent-Appellant.
ORDER AFFIRMED
Division III Opinion by JUDGE KUHN Dunn and Lipinsky, JJ., concur
NOT PUBLISHED PURSUANT TO C.A.R. 35(e) Announced September 18, 2025
Cynthia Mitchell, County Attorney, Kate H. Shafer, Special Assistant County Attorney, Pueblo, Colorado, for Petitioner-Appellee
Tezak Law, P.C., Mary Tezak, Florence, Colorado, for Respondent-Appellant ¶1 P.G. appeals the district court’s order authorizing involuntary
administration of his medication. We affirm the order.
I. Background
¶2 P.G. has been diagnosed with schizophrenia. Previously, the
district court had granted an extension of P.G.’s long-term care and
treatment at Health Solutions, a designated facility of the Colorado
Behavioral Health Administration. Then recently, at the request of
Health Solutions staff psychiatrist Arlene Shanklin, M.D., the
People filed a petition seeking authorization to involuntarily
administer Invega Sustenna (an antipsychotic medication) to P.G.
¶3 The district court held an evidentiary hearing on the petition.
Dr. Shanklin, who the parties stipulated was an expert in the field
of clinical psychiatry, testified for the People; P.G. testified on his
own behalf. The court found Dr. Shanklin’s testimony credible and
persuasive and adopted her opinions. The court further found that
the People had proved the necessary elements for the involuntary
administration of medication under People v. Medina, 705 P.2d 961,
973 (Colo. 1985), and issued an order authorizing Health Solutions
staff to administer Invega Sustenna to P.G. against his will.
1 II. Analysis
A. Legal Principles and Standard of Review
¶4 A person who is involuntarily committed retains the right to
refuse treatment. See id. at 971. Even so, a district court may
authorize the involuntary administration of medication if the People
establish each of the following elements by clear and convincing
evidence: (1) the person is incompetent to effectively participate in
the treatment decision; (2) the treatment is necessary to prevent a
significant and likely long-term deterioration in the person’s mental
health condition or to prevent the likelihood of the patient causing
serious harm to himself or others in the institution; (3) a less
intrusive treatment alternative is not available; and (4) the person’s
need for treatment is sufficiently compelling to override any bona
fide and legitimate interest of the person in refusing treatment. Id.
at 973.
¶5 In a sufficiency challenge, we review whether the evidence,
viewed as a whole and in the light most favorable to the People, is
sufficient to support the court’s order. People in Interest of R.K.L.,
2016 COA 84, ¶ 13. The testimony of the physician seeking to
2 administer treatment may be sufficient, without more, to satisfy the
Medina test. Id. at ¶ 30.
¶6 Application of the Medina test is a mixed question of fact and
law. People v. Marquardt, 2016 CO 4, ¶ 8. We defer to the district
court’s factual findings if they are supported by the record but
review the court’s legal conclusions de novo. Id. Both the
resolution of testimonial conflicts and the determination of witness
credibility are solely within the province of the fact finder. People in
Interest of Ramsey, 2023 COA 95, ¶ 23. When the evidence
supports the district court’s findings and conclusions, we will not
substitute our judgment for that of the district court. See People in
Interest of A.J.L., 243 P.3d 244, 255 (Colo. 2010).
B. Significant and Likely Long-Term Deterioration
¶7 P.G. does not contest the district court’s determination of the
first, third, or fourth elements of the Medina test. He contends only
that the evidence presented at the hearing was insufficient to prove
the second element. We disagree.
¶8 As noted, under the second Medina element, a court must
determine, by clear and convincing evidence, that the proposed
treatment is necessary either to prevent (1) a significant and likely
3 long-term deterioration in the patient’s mental condition or (2) the
likelihood of the patient causing serious harm to himself or others.
Medina, 705 P.2d at 973. These are “alternative factors.” Id. In
considering the first, the court focuses on “the nature and gravity of
the patient’s illness, the extent to which the medication is essential
to effective treatment, the prognosis without the medication, and
whether the failure to medicate will be more harmful to the patient
than any risks posed by the medication.” Id. The second
alternative considers whether, without the proposed treatment, the
patient will likely constitute a continuing and significant threat to
the safety of himself or others. Id. at 973-74.
¶9 The court determined that the People had proved both factors.
In considering the first alternative, the court found that, without
Invega Sustenna, P.G.’s prognosis was poor. In particular, the
court found credible Dr. Shanklin’s testimony that if P.G. stops
taking the medication, his mental health will decompensate within
a few weeks to a month, when the medication leaves his system.
The court also found that, at that time, he will show symptoms of
his illness, including hallucinations, delusions, a decrease in
wanting to move forward with or improve his life, and a decrease in
4 self-care. And the court found that, without the medication, P.G.
will likely return to illicit drug use, which will cause additional
decompensation.
¶ 10 We defer to the district court’s determination that Dr.
Shanklin was a credible and persuasive witness. See Marquardt,
¶ 8. Dr. Shanklin described the severity of P.G.’s illness and opined
that if he does not take the requested medication, there would be a
significant and likely long-term deterioration of his mental
condition. She described P.G.’s demonstrable improvement while
on a consistent Invega Sustenna regimen, including a significant
decrease in psychotic symptoms, hallucinations, and delusions,
and an increase in his ability to engage with his treatment team.
She noted, however, that his improvement does not mean that P.G.
is cured and the medication is no longer needed; instead,
schizophrenia requires ongoing treatment to maintain stability. She
opined that, upon ceasing medication, P.G.’s condition would
deteriorate in precisely the ways the court found. And she testified
that the failure to medicate him would be more harmful than the
risks posed by the requested medication.
5 ¶ 11 This record supports the district court’s determination that
the requested treatment is necessary to prevent a significant and
likely long-term deterioration in P.G.’s mental condition.
¶ 12 Nonetheless, P.G. asserts that the court’s analysis “boils down
to a finding that the [requested] medication has been effective” and
“leaves no room for [him] to ever be free from court-ordered
Free access — add to your briefcase to read the full text and ask questions with AI
25CA1232 Peo in Interest of PG 09-18-2025
COLORADO COURT OF APPEALS
Court of Appeals No. 25CA1232 Pueblo County District Court No. 23MH8 Honorable Amiel Markenson, Judge
The People of the State of Colorado,
Petitioner-Appellee,
In the Interest of P.G.,
Respondent-Appellant.
ORDER AFFIRMED
Division III Opinion by JUDGE KUHN Dunn and Lipinsky, JJ., concur
NOT PUBLISHED PURSUANT TO C.A.R. 35(e) Announced September 18, 2025
Cynthia Mitchell, County Attorney, Kate H. Shafer, Special Assistant County Attorney, Pueblo, Colorado, for Petitioner-Appellee
Tezak Law, P.C., Mary Tezak, Florence, Colorado, for Respondent-Appellant ¶1 P.G. appeals the district court’s order authorizing involuntary
administration of his medication. We affirm the order.
I. Background
¶2 P.G. has been diagnosed with schizophrenia. Previously, the
district court had granted an extension of P.G.’s long-term care and
treatment at Health Solutions, a designated facility of the Colorado
Behavioral Health Administration. Then recently, at the request of
Health Solutions staff psychiatrist Arlene Shanklin, M.D., the
People filed a petition seeking authorization to involuntarily
administer Invega Sustenna (an antipsychotic medication) to P.G.
¶3 The district court held an evidentiary hearing on the petition.
Dr. Shanklin, who the parties stipulated was an expert in the field
of clinical psychiatry, testified for the People; P.G. testified on his
own behalf. The court found Dr. Shanklin’s testimony credible and
persuasive and adopted her opinions. The court further found that
the People had proved the necessary elements for the involuntary
administration of medication under People v. Medina, 705 P.2d 961,
973 (Colo. 1985), and issued an order authorizing Health Solutions
staff to administer Invega Sustenna to P.G. against his will.
1 II. Analysis
A. Legal Principles and Standard of Review
¶4 A person who is involuntarily committed retains the right to
refuse treatment. See id. at 971. Even so, a district court may
authorize the involuntary administration of medication if the People
establish each of the following elements by clear and convincing
evidence: (1) the person is incompetent to effectively participate in
the treatment decision; (2) the treatment is necessary to prevent a
significant and likely long-term deterioration in the person’s mental
health condition or to prevent the likelihood of the patient causing
serious harm to himself or others in the institution; (3) a less
intrusive treatment alternative is not available; and (4) the person’s
need for treatment is sufficiently compelling to override any bona
fide and legitimate interest of the person in refusing treatment. Id.
at 973.
¶5 In a sufficiency challenge, we review whether the evidence,
viewed as a whole and in the light most favorable to the People, is
sufficient to support the court’s order. People in Interest of R.K.L.,
2016 COA 84, ¶ 13. The testimony of the physician seeking to
2 administer treatment may be sufficient, without more, to satisfy the
Medina test. Id. at ¶ 30.
¶6 Application of the Medina test is a mixed question of fact and
law. People v. Marquardt, 2016 CO 4, ¶ 8. We defer to the district
court’s factual findings if they are supported by the record but
review the court’s legal conclusions de novo. Id. Both the
resolution of testimonial conflicts and the determination of witness
credibility are solely within the province of the fact finder. People in
Interest of Ramsey, 2023 COA 95, ¶ 23. When the evidence
supports the district court’s findings and conclusions, we will not
substitute our judgment for that of the district court. See People in
Interest of A.J.L., 243 P.3d 244, 255 (Colo. 2010).
B. Significant and Likely Long-Term Deterioration
¶7 P.G. does not contest the district court’s determination of the
first, third, or fourth elements of the Medina test. He contends only
that the evidence presented at the hearing was insufficient to prove
the second element. We disagree.
¶8 As noted, under the second Medina element, a court must
determine, by clear and convincing evidence, that the proposed
treatment is necessary either to prevent (1) a significant and likely
3 long-term deterioration in the patient’s mental condition or (2) the
likelihood of the patient causing serious harm to himself or others.
Medina, 705 P.2d at 973. These are “alternative factors.” Id. In
considering the first, the court focuses on “the nature and gravity of
the patient’s illness, the extent to which the medication is essential
to effective treatment, the prognosis without the medication, and
whether the failure to medicate will be more harmful to the patient
than any risks posed by the medication.” Id. The second
alternative considers whether, without the proposed treatment, the
patient will likely constitute a continuing and significant threat to
the safety of himself or others. Id. at 973-74.
¶9 The court determined that the People had proved both factors.
In considering the first alternative, the court found that, without
Invega Sustenna, P.G.’s prognosis was poor. In particular, the
court found credible Dr. Shanklin’s testimony that if P.G. stops
taking the medication, his mental health will decompensate within
a few weeks to a month, when the medication leaves his system.
The court also found that, at that time, he will show symptoms of
his illness, including hallucinations, delusions, a decrease in
wanting to move forward with or improve his life, and a decrease in
4 self-care. And the court found that, without the medication, P.G.
will likely return to illicit drug use, which will cause additional
decompensation.
¶ 10 We defer to the district court’s determination that Dr.
Shanklin was a credible and persuasive witness. See Marquardt,
¶ 8. Dr. Shanklin described the severity of P.G.’s illness and opined
that if he does not take the requested medication, there would be a
significant and likely long-term deterioration of his mental
condition. She described P.G.’s demonstrable improvement while
on a consistent Invega Sustenna regimen, including a significant
decrease in psychotic symptoms, hallucinations, and delusions,
and an increase in his ability to engage with his treatment team.
She noted, however, that his improvement does not mean that P.G.
is cured and the medication is no longer needed; instead,
schizophrenia requires ongoing treatment to maintain stability. She
opined that, upon ceasing medication, P.G.’s condition would
deteriorate in precisely the ways the court found. And she testified
that the failure to medicate him would be more harmful than the
risks posed by the requested medication.
5 ¶ 11 This record supports the district court’s determination that
the requested treatment is necessary to prevent a significant and
likely long-term deterioration in P.G.’s mental condition.
¶ 12 Nonetheless, P.G. asserts that the court’s analysis “boils down
to a finding that the [requested] medication has been effective” and
“leaves no room for [him] to ever be free from court-ordered
medication.” We disagree with this premise. For starters, the
effectiveness of the medication is indeed a part of the court’s inquiry
into the second Medina element. See Medina, 705 P.2d at 973.
Moreover, Dr. Shanklin’s testimony, which the district court
credited on this point, demonstrates that ongoing treatment will be
required for P.G. to maintain a stable mental condition. And P.G.
testified that, without a court order, he would stop taking the
Invega Sustenna. Thus, whether P.G. requires court-ordered
medication in the future will depend on the course of his treatment,
the efficacy of that treatment, his choices, and the other attendant
circumstances at that time.
¶ 13 Having concluded that sufficient evidence supports the court’s
finding as to the deterioration factor of Medina’s second element,
and because the second Medina element is phrased in the
6 disjunctive, we need not reach P.G.’s contention that the court also
erred by finding medication is necessary to prevent the likelihood of
P.G. causing serious harm to himself. See id.; see also Lombard v.
Colo. Outdoor Educ. Ctr., Inc., 187 P.3d 565, 571 (Colo. 2008) (“[T]he
disjunctive use of the word ‘or’ marks distinctive categories.”).
III. Disposition
¶ 14 The order is affirmed.
JUDGE DUNN and JUDGE LIPINSKY concur.